1-5 of 5
Silke Gillessen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)

Free
Andreas Müller, Arnoud J Templeton, Stefanie Hayoz, Ursina Zürrer, Ursula Hasler-Strub, Michael Schwitter, Tilly Nothelfer, Konstantin Dedes, Khalil Zaman, Marc Küng, Lorenzo Rossi, Alexander Schreiber, Mathias Fehr, Ulrich Güller, Marcus Vetter, Razvan Popescu, Patrik Weder, Roman Inauen, Catrina Uhlmann Nussbaum, Claudine Egger, Corinne Cescato, Bettina Seifert, David R. Thorn, Corinne Schär, Silke Gillessen, Roger von Moos
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS5-06.
https://doi.org/10.1158/1557-3265.SABCS24-PS5-06
Published: 13 June 2025
View articletitled, Abstract PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)
Journal Articles

Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Available to Purchase
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A.J. Buck, Ron H.J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus Joerger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1887–1893.
https://doi.org/10.1158/1078-0432.CCR-22-3360
Published: 15 May 2023
View articletitled, Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Free
Richard J. Rebello, Christoph Oing, Silke Gillessen, Robert G. Bristow
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1699–1701.
https://doi.org/10.1158/1078-0432.CCR-18-3401
Published: 15 March 2019
View articletitled, TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Open the PDF for TP53 and Prognosis in mCRPC Survival: Biology or Coincidence? in another window
Journal Articles

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Free
Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, Judith Scranton, Michael N. Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1925–1934.
https://doi.org/10.1158/1078-0432.CCR-13-1869
Published: 31 March 2014
View articletitled, Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)

Free
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jaggi, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droege, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, Silke Gillessen, for the Swiss Group for Clinical Cancer Research (SAKK)
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6049–6057.
https://doi.org/10.1158/1078-0432.CCR-12-2219
Published: 06 November 2012
View articletitled, Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Open the PDF for Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07) in another window